ArticleMicrobial cell factories2025
Metabolic engineering of Phaeodactylum tricornutum for heterologous production of the plant triterpenoid friedelin.
Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFriedelin is a pharmacologically valuable pentacyclic triterpenoid with anti-inflammatory, anticancer, antiviral, and antiobesity properties. Conventional methods of friedelin production rely on solvent-intensive extraction from plant biomass, which is often expensive, inefficient, and environmentally unsustainable. Phaeodactylum tricornutum, a model marine diatom with a unique chimeric sterol biosynthetic pathway and native oxidosqualene accumulation, presents a promising platform for heterologous triterpenoid biosynthesis.
resultsIn this study, the TwOSC4 gene from Tripterygium wilfordii, which encodes friedelin synthase, was successfully expressed in P. tricornutum via biolistic transformation. As a result, two transgenic strains, Pt-OSC4-20 and Pt-OSC4-48, were confirmed to express TwOSC4 at both transcript and protein levels. Liquid chromatography–quadrupole time-of-flight mass spectrometry (LC-QTOF/MS) analysis validated friedelin production in these strains, with a baseline accumulation of 26 ng/mL under standard conditions. Upon treatment with Ro 48-8071, an oxidosqualene cyclase inhibitor that suppresses endogenous sterol biosynthesis, friedelin production increased up to 55 ng/mL. Nile red staining revealed increased lipid droplet formation in the transgenic strains, suggesting the possible intracellular storage of friedelin. Importantly, transgene expression did not impair cell growth, indicating the metabolic compatibility of the host with exogenous triterpenoid synthesis.
conclusionsThis is the first study to demonstrate successful biosynthesis of friedelin in a microalgal system, highlighting the potential of P. tricornutum as a sustainable phototrophic chassis for the production of plant-derived triterpenoids. Unlike yeast-based systems, which require extensive metabolic amplification, P. tricornutum enables simpler genetic engineering and simultaneous coproduction of valuable compounds, such as fucoxanthin and Omega-3 Eicosapentaenoic Acid (EPA). These findings lay the groundwork for further strain optimization aimed at increasing friedelin yield and broadening the scope of triterpenoid biosynthesis in microalgae.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.